Results 271 to 280 of about 111,871 (303)
Some of the next articles are maybe not open access.
Clinical perspectives of PARP inhibitors
Pharmacological Research, 2005Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. At the same time, PARP activation is also relevant for the ability of cells to repair injured DNA. Thus, depending on the circumstances, pharmacological inhibitors of PARP may be able to attenuate ischemic and inflammatory
GRAZIANI, GRAZIA, Szabo C.
openaire +3 more sources
PARP inhibitors for cancer therapy
Expert Reviews in Molecular Medicine, 2005Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by the base-excision pathway or cell death. A family of 18 PARPs has been identified, but only the most
openaire +3 more sources
The Vasoactivity of PARP Inhibitors
2015PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire +2 more sources
PARP inhibitors in ovarian cancer
Seminars in OncologyPoly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency.
Ian S. Goldlust +2 more
openaire +2 more sources
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Ca-A Cancer Journal for Clinicians, 2011Timothy A Yap, Johann Sebastian de Bono
exaly